Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rufinamide - Novartis

Drug Profile

Rufinamide - Novartis

Alternative Names: Banzel; CGP 33101; E 2080; Inovelon; RUF 331; SYN 111; Xilep™

Latest Information Update: 31 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Biotie Therapies Corp.; Eisai Co Ltd
  • Class Amides; Antiepileptic drugs; Fluorobenzenes; Small molecules; Triazoles
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Lennox-Gastaut syndrome
  • No development reported Epilepsy
  • Discontinued Generalised anxiety disorder; Neuropathic pain

Most Recent Events

  • 18 Dec 2018 Eisai initiates an expanded-access programme for Lennox Gastaut Syndrome in Poland (NCT03778424)
  • 29 Jun 2018 Preregistration for Lennox-Gastaut syndrome (Adjunctive treatment, In adults, In children, In adolescents) in European Union (PO)
  • 29 Jun 2018 CHMP recommended change in terms of the MAA for Lennox-Gastaut syndrome in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top